Tobias Boch
Overview
Explore the profile of Tobias Boch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1003
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lutz R, Grunschlager F, Simon M, Awwad M, Bauer M, Yousefian S, et al.
Nat Commun
. 2024 Nov;
15(1):10396.
PMID: 39613747
The long-term consequences of cancer and its therapy on the patients' immune system years after cancer-free survival remain poorly understood. Here, we present an in-depth characterization of the bone marrow...
2.
Leppa A, Grimes K, Jeong H, Huang F, Andrades A, Waclawiczek A, et al.
Nat Genet
. 2024 Nov;
56(12):2790-2803.
PMID: 39587361
Chromosomal instability is a major driver of intratumoral heterogeneity (ITH), promoting tumor progression. In the present study, we combined structural variant discovery and nucleosome occupancy profiling with transcriptomic and immunophenotypic...
3.
Abba M, Riabov V, Nowak D, Hofmann W, Boch T
Front Oncol
. 2024 Jun;
14:1404817.
PMID: 38835379
Myelodysplastic neoplasms (MDS) are a heterogenous group of clonal stem cell disorders characterized by dysplasia and cytopenia in one or more cell lineages. Anemia is a very common symptom that...
4.
Dreikhausen L, Klupsch A, Wiest I, Xiao Q, Schulte N, Betge J, et al.
BMC Cancer
. 2024 Apr;
24(1):526.
PMID: 38664720
Background: Panel gene sequencing is an established diagnostic tool for precision oncology of solid tumors, but its utility for the treatment of cancers of the digestive system in clinical routine...
5.
Streuer A, Jann J, Boch T, Mossner M, Riabov V, Schmitt N, et al.
Ann Hematol
. 2024 Feb;
103(4):1221-1233.
PMID: 38413410
In low-risk Myelodysplastic Neoplasms (MDS), increased activity of apoptosis-promoting factors such as tumor necrosis factor (TNFα) and pro-apoptotic Fas ligand (CD95L) have been described as possible pathomechanisms leading to impaired...
6.
Hirschinger H, Jaeger E, Nittka S, Hetjens S, Lorenz C, Remi C, et al.
BMC Palliat Care
. 2024 Jan;
23(1):8.
PMID: 38172871
Background: Intranasal (i.n.) drug application is a widely known and low-invasive route of administration that may be able to achieve rapid symptom control in terminally ill patients. According to the...
7.
Michaeli D, Michaeli T, Albers S, Boch T, Michaeli J
Eur J Health Econ
. 2023 Nov;
25(6):979-997.
PMID: 37962724
Background: Over the past decades, US Congress enabled the US Food and Drug Administration (FDA) to facilitate and expedite drug development for serious conditions filling unmet medical needs with five...
8.
Michaeli D, Michaeli J, Albers S, Boch T, Michaeli T
Am J Cardiovasc Drugs
. 2023 Jul;
23(5):477-495.
PMID: 37486464
Despite treatment with statins, patients with elevated low-density lipoprotein cholesterol (LDL-C) and triglycerides remain at increased risk for adverse cardiovascular events. Consequently, novel pharmaceutical drugs have been developed to control...
9.
Boch T, Kohler J, Janning M, Loges S
Cancer Biol Med
. 2022 Dec;
19(11).
PMID: 36476337
Lung cancer remains the leading cause of cancer-associated mortality worldwide, but with the emergence of oncogene targeted therapies, treatment options have tremendously improved. Owing to their biological relevance, members of...
10.
Andresen C, Boch T, Gegner H, Mechtel N, Narr A, Birgin E, et al.
Front Mol Biosci
. 2022 Sep;
9:932261.
PMID: 36090025
Analyses of metabolic compounds inside cells or tissues provide high information content since they represent the endpoint of biological information flow and are a snapshot of the integration of many...